

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
 (Not for submission under 37 CFR 1.99)

Application Number		10522134
Filing Date		
First Named Inventor	Steven Jones	
Art Unit		
Examiner Name	Sharon L. Hurt	
Attorney Docket Number	85084-402 MRW	

U.S. PATENTS**Remove**

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add**U.S. PATENT APPLICATION PUBLICATIONS****Remove**

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button

Add**FOREIGN PATENT DOCUMENTS****Remove**

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add**NON-PATENT LITERATURE DOCUMENTS****Remove**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ts
--------------------	---------	---	----

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10522134	
Filing Date		
First Named Inventor	Steven Jones	
Art Unit		
Examiner Name	Sharon L. Hurl	
Attorney Docket Number	85084-402 MRW	

1	Replication-Competent or Attenuated, Nonpropagating Vesicular Stomatitis Viruses Expressing Respiratory Syncytial Virus (RSV) Antigens Protect Mice against RSV Challenge; Jeffrey S. Kahn et al.; Journal of Virology, Nov. 2001, p. 11079-11087; Vol. 75, No. 22	<input type="checkbox"/>
2	Development of a Preventive Vaccine for Ebola Virus Infection in Primates; Nancy J. Sullivan et al.; Letters to Nature, 2000 Macmillan Magazines Ltd., Nature/Vol 406/30 November 2000/www.nature.com, pages 605-609	<input type="checkbox"/>
3	DNA Vaccines Expressing either the GP or NP Genes of Ebola Virus Protect Mice from lethal Challenge; Loma Vanderzanden; Virology Division, United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland 21702-5011; and PowderJect Vaccines, Inc. Madison Wisconsin 53711; Virology 248, 134-144 (1998) Article No. VY989176, pages 134-144	<input type="checkbox"/>
4	Vaccination with a Recombinant Vesicular Stomatitis Virus Expressing an Influenza Virus Hemagglutinin Provides Complete Protection from Influenza Virus Challenge; Anjeanette Roberts et al.; Journal of Virology, June 1998, p. 4704-4711; American Society for Microbiology; Vol. 72, No. 6	<input type="checkbox"/>
5	Glycoprotein Exchange Vectors Based on Vesicular Stomatitis Virus Allow Effective Boosting and Generation of Neutralizing Antibodies to a Primary Isolate of Human Immunodeficiency Virus Type 1; Nina F. Rose et al. Journal of Virology, Dec 2000, p. 10903-10910, American Society for Microbiology; Vol. 74, No. 23	<input type="checkbox"/>
6	High-Efficiency Incorporation of Functional Influenza Virus Glycoproteins into Recombinant Vesicular Stomatitis Viruses; Evelyne Kretzschmar et al.; Journal of Virology, Aug. 1997, p. 5982-5989, American Society for Microbiology, Vol. 71, No. 8	<input type="checkbox"/>
7	Towards a Vaccine Against Ebola Virus; Thomas W Geisbert et. al.; ISSN 1476-0584; Expert Rev. Vaccines 2(6), 777-789 (2003)	<input type="checkbox"/>
8	Identification of the Ebola Virus Glycoprotein as the Main Viral Determinant of Vascular Cell Cytotoxicity and Injury; Zhi-Tong Yang et al., 2000 Nature America Inc. http://medicine.nature.com, Volume 6, Number 8, August 2000, p. 886-889	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.